MA-ALLURION-TECHNOLOGIES
26.1.2021 13:02:12 CET | Business Wire | Press release
Allurion® Technologies , a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced a major milestone for its AllurionTM Weight Loss Program with the launch of its new digital health offering featuring the Allurion TM Health Tracker smartwatch, Allurion® Connected Scale, Allurion® mobile app, and the Allurion TM Clinic Dashboard, the first in a series of new provider services that make up the Allurion TM Virtual Care Suite.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005074/en/
The Allurion Connected Scale and Health Tracker measure all aspects of body composition including weight, body fat, muscle mass, as well as activity data such as steps, exercise, and sleep. These measurements effortlessly sync with the Allurion mobile app, which charts and analyzes the data, provides real-time insights to the user, and enables sharing with their provider and care team.
The Allurion Clinic Dashboard helps providers understand their aggregate patient results and access real-time insights to tailor care, ultimately leading to improved outcomes. The Allurion Clinic Dashboard is a turnkey solution that enables providers to track a variety of clinic-level metrics such as weight loss and patient engagement over time, benchmarking their performance with other clinics across the globe.
Additional capabilities of the Allurion Virtual Care Suite will be released throughout 2021, making it simple for providers to monitor, communicate and deliver care via a suite of tools which include telehealth and AI-powered weight-loss guidance. This suite, available to all providers who offer the Allurion Program, enables seamless ongoing support and leads to markedly improved patient satisfaction.
“The Allurion Virtual Care Suite is designed to work hand-in-hand with the Elipse® Balloon and our nutritional and behavior change program to deliver life-changing results to consumers and real-time data and insights to our providers,” said Shantanu Gaur, M.D., Allurion’s co-founder and Chief Executive Officer. “Our digital health offering creates an ecosystem for consumers and providers that will not only improve short-term outcomes but also facilitate weight management over a lifetime.”
As a further demonstration of Allurion’s commitment to consumer satisfaction and best-in-class results, the company is also announcing today the launch of the Allurion Assurance Plus Warranty program. Allurion patients around the world will now automatically be enrolled in the new Allurion Warranty program at no charge. The Allurion Assurance Plus Warranty program provides patients piece of mind that qualifying rare events related to the Elipse® Balloon will be eligible for coverage and out-of-pocket financial assistance.
“Allurion is committed to provide patients a best-in-class experience, and their safety is our top priority,” said Ram Chuttani, M.D., Allurion’s Chief Medical Officer “We are delighted to launch the Allurion Assurance Plus Warranty to give our patients added comfort and confidence as they proceed through their weight loss journey.”
About Allurion Technologies
Allurion Technologies is dedicated to helping people realize a healthy life with innovative, scalable and trusted weight loss experiences. The company's flagship product, the Allurion Program, is a 360-degree weight loss experience featuring the Elipse Balloon, the world’s first and only swallowable, procedureless gastric balloon for weight loss, the Allurion Honeymoon from Hunger nutritional and behavior change program, and the Allurion Virtual Care Suite including the Allurion Connected Scale, Allurion Health Tracker smartwatch, Allurion mobile app, Allurion Clinic Dashboard and Allurion Insights Portal. Learn more about Allurion online at www.allurion.com . Allurion and Elipse are trademarks of Allurion Technologies, Inc. in the United States and countries around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005074/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom